Geode Capital Management
AMLX icon

Geode Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Geode Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.9M Buy
2,335,315
+124,383
+6% +$1.92M ﹤0.01% 1723
2026
Q1 		$30.7M Buy
2,210,932
+45,398
+2% +$639K ﹤0.01% 1770
2025
Q4 		$26.2M Buy
2,165,534
+353,495
+20% +$4.8M ﹤0.01% 1868
2025
Q3 		$24.6M Buy
1,812,039
+119,626
+7% +$1.13M ﹤0.01% 1893
2025
Q2 		$10.9M Buy
1,692,413
+886,252
+110% +$4.31M ﹤0.01% 2311
2025
Q1 		$2.85M Buy
806,161
+238,258
+42% +$848K ﹤0.01% 2913
2024
Q4 		$2.15M Buy
567,903
+16,864
+3% +$79.4K ﹤0.01% 3096
2024
Q3 		$1.79M Buy
551,039
+82,173
+18% +$185K ﹤0.01% 3164
2024
Q2 		$891K Sell
468,866
-597,379
-56% -$1.16M ﹤0.01% 3345
2024
Q1 		$3.03M Buy
1,066,245
+35,529
+3% +$465K ﹤0.01% 2941
2023
Q4 		$15.2M Buy
1,030,716
+48,648
+5% +$746K ﹤0.01% 2076
2023
Q3 		$18M Buy
982,068
+44,071
+5% +$932K ﹤0.01% 1887
2023
Q2 		$20.2M Buy
937,997
+47,015
+5% +$1.27M ﹤0.01% 1848
2023
Q1 		$26.1M Buy
890,982
+37,069
+4% +$1.29M ﹤0.01% 1624
2022
Q4 		$31.6M Buy
853,913
+218,357
+34% +$7.75M ﹤0.01% 1472
2022
Q3 		$17.9M Buy
635,556
+404,139
+175% +$10.1M ﹤0.01% 1816
2022
Q2 		$4.46M Buy
231,417
+41,267
+22% +$490K ﹤0.01% 2760
2022
Q1 		$2.44M Buy
+190,150
New +$4.29M ﹤0.01% 3159

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Geode Capital Management's AMLX Position: Q2 2026 in Review

Geode Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 5.6% in Q2 2026, buying an estimated $1.92M and bringing the position to 2,335,315 shares worth $41.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1723.

Geode Capital Management first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Geode Capital Management held 2,335,315 shares of Amylyx Pharmaceuticals worth $41.9M as of Q2 2026.
  • Geode Capital Management bought 124,383 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.92M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1723 holding.
  • Geode Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.